Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.

Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) pa- tient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal...

ver descrição completa

Detalhes bibliográficos
Autores: Villanueva, Bernat, Iriarte, Adriana, Torres Iglesias, Raquel, Muñoz Bolaño, Miriam, Cerdà, Pau, Riera Mestre, Antoni
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/204935
Acesso em linha:https://hdl.handle.net/2445/204935
Access Level:acceso abierto
Palavra-chave:Angiogènesi
Vasos sanguinis
Hemorràgia
Neovascularization
Blood vessels
Hemorrhage
id ES_68cb4182b162cbf50d65c02ce548d8a2
oai_identifier_str oai:recercat.cat:2445/204935
network_acronym_str ES
network_name_str España
repository_id_str
spelling Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.Villanueva, BernatIriarte, AdrianaTorres Iglesias, RaquelMuñoz Bolaño, MiriamCerdà, PauRiera Mestre, AntoniAngiogènesiVasos sanguinisHemorràgiaNeovascularizationBlood vesselsHemorrhageHerein, we present the first described hereditary hemorrhagic telangiectasia (HHT) pa- tient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal telangiectasia is one of the major involvements that can produce chronic severe iron-deficiency anemia. Nowadays, support treatment with iron replacement therapy, red blood cell transfusions, and antiangiogenic drugs—mainly bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)—are the main therapeutic options for this complication. The evidence of alternative drugs in patients with failure to this approach, such as tachyphylaxis to bevacizumab, is scarce. Aflibercept is a VEGF inhibitor with antiangiogenic properties approved for the treatment of different types of cancer and ocular neovascularization diseases.MDPI2023202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion5 p.application/pdfhttps://hdl.handle.net/2445/204935Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/medicina59091533Medicina (Kaunas), 2023, vol. 59, num.9https://doi.org/10.3390/medicina59091533cc-by (c) Villanueva, Bernat et al., 2023http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2049352026-05-29T05:05:01Z
dc.title.none.fl_str_mv Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
title Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
spellingShingle Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
Villanueva, Bernat
Angiogènesi
Vasos sanguinis
Hemorràgia
Neovascularization
Blood vessels
Hemorrhage
title_short Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
title_full Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
title_fullStr Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
title_full_unstemmed Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
title_sort Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
dc.creator.none.fl_str_mv Villanueva, Bernat
Iriarte, Adriana
Torres Iglesias, Raquel
Muñoz Bolaño, Miriam
Cerdà, Pau
Riera Mestre, Antoni
author Villanueva, Bernat
author_facet Villanueva, Bernat
Iriarte, Adriana
Torres Iglesias, Raquel
Muñoz Bolaño, Miriam
Cerdà, Pau
Riera Mestre, Antoni
author_role author
author2 Iriarte, Adriana
Torres Iglesias, Raquel
Muñoz Bolaño, Miriam
Cerdà, Pau
Riera Mestre, Antoni
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Angiogènesi
Vasos sanguinis
Hemorràgia
Neovascularization
Blood vessels
Hemorrhage
topic Angiogènesi
Vasos sanguinis
Hemorràgia
Neovascularization
Blood vessels
Hemorrhage
description Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) pa- tient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal telangiectasia is one of the major involvements that can produce chronic severe iron-deficiency anemia. Nowadays, support treatment with iron replacement therapy, red blood cell transfusions, and antiangiogenic drugs—mainly bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)—are the main therapeutic options for this complication. The evidence of alternative drugs in patients with failure to this approach, such as tachyphylaxis to bevacizumab, is scarce. Aflibercept is a VEGF inhibitor with antiangiogenic properties approved for the treatment of different types of cancer and ocular neovascularization diseases.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/204935
url https://hdl.handle.net/2445/204935
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/medicina59091533
Medicina (Kaunas), 2023, vol. 59, num.9
https://doi.org/10.3390/medicina59091533
dc.rights.none.fl_str_mv cc-by (c) Villanueva, Bernat et al., 2023
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Villanueva, Bernat et al., 2023
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5 p.
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409985298956288
score 15.811543

Registos relacionados